The link below will bring up HHI Gambler's post of Dr. Lalezari's 12/8/21 email to colleagues at the FDA and various colleges about Leronlimab. I suspect everyone has read it, but I think it is worth reviewing in view of Dr. L's new position with the company. I think you are correct when you said he talked about mismanagement, but I could not find that one.
Here is a link to a good article Drs. Lalezari and Seethamraju wrote on 5/7/21 about the benefit of Leronlimab for critically ill Covid patients.